Overview

• SCC occurs when the squamous cells of the skin are damaged and begin to grow out of control. 
• Typically, SCC starts as a small area of flaky skin that gets larger over time. 
• SCC is the second most common form of skin cancer, after basal cell carcinoma, and is more common than breast, lung and prostate cancer combined. 
• SCC is normally very treatable if caught early. But, it can be very aggressive if it spreads to other parts of the body 

• In non-Hispanic white individuals, the lifetime risk for developing SCC is 14 percent to 20 percent 
• The incidence of SCC in men is two to three times the incidence in women 
• SCC increases dramatically with age. Estimates for average age at first diagnosis range from mid-30s to early 70s 
• In the United States, the incidence is increased in southern states where there is greater UV exposure
• Increased and prolonged exposure to UV rays – such as tanning beds, jobs that require days spent in the sun, snow sports and other outdoor sports, such as golf – can increase the risk for SCC
• An estimated two million new cases of SCC are estimated to be diagnosed per year in the United States 
• SCC is the most common form of skin cancer among African Americans

While clinical presentation of SCC can vary, it most often occurs as a 0.5 to 1.5 cm firm, sometimes tender, pink to red papule, nodule, or plaque. It may include ulceration, easy bleeding and inflammation. Actinic keratosis and SCC in situ (also called Bowen's Disease) are precursors of SCC.

1. The DecisionDx-SCC test is the only test proven to assess the risk of regional or distant metastasis for SCC 
2. More than 100,000 skin cancer patients have relied on Castle Biosciences’ tests for insights to help guide their treatment decisions 
3. DecisionDx-SCC test complements major SCC treatment guidelines 

You may be a candidate for the DecisionDx-SCC test if:

• You’ve been diagnosed with cutaneous SCC within the last three years
• You have one or more high-risk factors